Navigation Links
Phase II study shows new cancer drug combination significantly delays breast cancer progression
Date:9/24/2011

Stockholm, Sweden: The first randomised trial to investigate the use of trastuzumab emtansine (T-DM1) an antibody-guided drug for the initial treatment of HER2- (human epidermal growth factor receptor-2) positive metastatic breast cancer has shown that it makes a significant difference to the time women live without their disease worsening.

Dr Sara Hurvitz, one of the trial investigators, will tell the 2011 European Multidisciplinary Cancer Congress [1] in Stockholm today (Sunday 25 September): "Our results showed that patients with metastatic breast cancer who received T-DM1 had a 41% improvement in the time they lived without their breast cancer worsening compared to those who received standard docetaxel chemotherapy plus trastuzumab. These provocative Phase II data illustrate that first-line treatment with T-DM1 provides a longer time for patients to live without cancer progression and with fewer side effects than standard chemotherapy plus trastuzumab."

Trastuzumab emtansine (T-DM1) is a novel type of cancer therapy known as an antibody drug conjugate (ADC). It combines the monoclonal antibody, trastuzumab, with a potent cytotoxic agent DM1 [2] through a stable linker and uses the HER2 targeting properties of trastuzumab to deliver the cell-killing agent DM1 into the cancer cells.

Dr Hurvitz, Director of the Breast Oncology Program for the Division of Hematology/ Oncology at The University of California, Los Angeles (UCLA), USA, will say that "T-DM1 is unique because it retains the cancer fighting properties of trastuzumab and delivers the DM1 agent directly to the tumour cell for destruction, while limiting exposure of the free DM1 drug to normal cells. This explains why patients who received T-DM1 had fewer side effects compared to those assigned to the chemotherapy-containing control arm in this study."

T-DM1 is specifically designed to attach trastuzumab to DM1 using a stable linker. The bound DM1 has little toxicit
'/>"/>

Contact: Kay Roche
kayroche@gmail.com
ECCO-the European CanCer Organisation
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
2. New High Purity Immunoglobulin Enters Phase III in Europe and the US
3. Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium
4. Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial
5. Askthedoctor.com Makes Medical Information More Accessible to the Public by Completing Phase 1 of US Expansion
6. Intellicate Announces New “Phased Return to Work” (PRtW) Service
7. Southampton scientists begin Phase II patient trial for new asthma treatment
8. Pilot Testing Phase Ends; Expansion Of Sales Force Begins
9. New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
10. Phase II study of an oral therapy for Gaucher disease yields positive results
11. Accumed Research Associates Expands Capabilities In Phase I and Bioequivalence Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Results from a large observational study reported ... is superior to heparin in the absence ... in patients with non-ST segment elevation acute ... (PCI)., European and US NSTE-ACS guidelines currently ... unfractionated heparin plus GP IIb/IIIa receptor inhibitors ...
(Date:5/22/2013)... NY (PRWEB) May 22, 2013 ... an exclusive partnership with Aurora Financial Systems, Inc. ... tool to companies that offer Medicare Advantage Health ... members for completing 3 out of 12 preferred ... product launched March 2013, and provides an incentive ...
(Date:5/22/2013)... MA (PRWEB) May 22, 2013 In ... hit the country’s fields and courts with donated ... Sports, a Massachusetts-based nonprofit dedicated to partnering with manufacturers ... is celebrating the donation of $8.8 million in sports ... more than a half-million kids outfitted for physical activity. ...
(Date:5/22/2013)... York City, New York (PRWEB) May 22, 2013 ... American: Causes, Culture, Consequences, and Cost ” article published recently ... obesity is fully justified. The Centers for Disease Control ... U.S. adults aged 20 and over are overweight, 35.7% are ... facts are highlighted in this investigative article. In particular, the ...
(Date:5/22/2013)... 2013 Following the success of last ... Fit Body Boot Camp Kincardine has announced it ... Challenge starting on June 3rd at its Kincardine ... Street, Kincardine, Ontario.     , Fit Body Boot Camp’s 1,000 ... local community residents to lose a total of 1,000 ...
Breaking Medicine News(10 mins):Health News:Registry questions superiority of bivalirudin over heparin 2Health News:Integrated Printing Solutions and Aurora Financial Systems, Inc. Create Partnership for Healthcare Incentive Card 2Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 2Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 3Health News:Black American Obesity Examined In The Latest FinancesOnline.com Article 2Health News:Black American Obesity Examined In The Latest FinancesOnline.com Article 3Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 2Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 3
... ... inflammatory bowel disease (IBD) research were awarded the Crohn,s & Colitis Foundation,s prestigious ... & Research Conference ( http://www.advancesinibd.com/ ) in Hollywood, Florida on December 4th. ... New ...
... , , ... a new market research report is available in ... strategic assessment of the competitive environment is widely ... responsibilities, the task crucial to business survival, growth ...
... 17 Good Samaritan Hospital is changing the way women manage ... Good Samaritan Hospital Women,s Center For Bladder & Pelvic Health. , ... - lack of bladder control (urinary incontinence) and slippage of the ... women report some degree of urinary leakage and one out of ...
... 2009 Canadian teenagers are among the largest consumers ... drug on young brains are worse than originally thought, ... psychiatric researcher from the Research Institute of the McGill ... Neurobiology of Disease , suggests that daily consumption of ...
... particle might someday ease accompanying lung infections , THURSDAY, Dec. ... infected with the swine flu virus, and researchers say they,ve ... the severity of the illness appears to be a molecule ... off germs and disease. Researchers who analyzed levels of the ...
... ... examinations underscore the important role that competent, educated CT technologists play in minimizing ... , ... NM (Vocus) December 16, 2009 -- Two recent studies examining radiation doses delivered ...
Cached Medicine News:Health News:Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases 2Health News:Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases 3Health News:Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases 4Health News:Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases 5Health News:Reportlinker Adds Top Ten World's Leading Life Science Intermediates Companies 2Health News:Good Samaritan Hospital Launches Women's Center For Bladder & Pelvic Health 2Health News:Good Samaritan Hospital Launches Women's Center For Bladder & Pelvic Health 3Health News:ASRT Supports Efforts to Minimize CT Radiation Dose 2Health News:ASRT Supports Efforts to Minimize CT Radiation Dose 3Health News:ASRT Supports Efforts to Minimize CT Radiation Dose 4
(Date:5/22/2013)... 22, 2013   Upsher-Smith Laboratories, Inc. ... its global Phase III clinical trial for ... for the management of epilepsy in adults, ... is specifically engineered to provide convenient once-daily ... levels observed with currently available treatment options.  ...
(Date:5/22/2013)... 22, 2013  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ... of the company at the following conferences. , ... date: Wednesday May 29, 2013 , Presentation time: 12:00 ... Conference , Presentation date: Wednesday June 5, 2013 ... A live webcast and 30-day archive of these ...
(Date:5/22/2013)... REHOVOT, Israel , May 22, 2013 ... a leading developer and provider of microRNA-based molecular diagnostics, ... President and Chief Executive Officer of Rosetta Genomics, will ... Conference taking place from June 3-6, 2013 in New ... Tuesday, June 4 th at 2:00 p.m. Eastern ...
Breaking Medicine Technology:Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 2Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 3Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 4Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences 2Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 2Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 3
... NEW YORK, Nov. 8, 2010 Reportlinker.com ... is available in its catalogue: ... Technology platforms, key players, and early pipeline ... Therapeutic vaccines promise a ...
... Nov. 8, 2010 Reportlinker.com announces that ... in its catalogue: Opportunities ... growth in key regions and therapeutic areas ... The flurry of recent industry acquisitions ...
Cached Medicine Technology:Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 2Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 3Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 4Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 5Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 6Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 7Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 8Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates 9Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 2Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 3Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 4Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 5Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 6Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 7
... The Summit SI Spinal Fixation ... for rigid posterior fixation of ... spine. The simplicity and versatility ... optimize the construct based on ...
OctaFix is designed specifically to provide stability and fixation where it is most needed....
...
...
Medicine Products: